Cargando…
An Overview of Repurposed Drugs for Potential COVID-19 Treatment
The COVID-19 pandemic caused by SARS-CoV-2 has placed severe constraints on healthcare systems around the globe. The SARS-CoV-2 virus has caused upheaval in the healthcare and economic sectors worldwide. On the 20th of May 2020, the World Health Organisation declared COVID-19 a global pandemic due t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774286/ https://www.ncbi.nlm.nih.gov/pubmed/36551336 http://dx.doi.org/10.3390/antibiotics11121678 |
_version_ | 1784855370531864576 |
---|---|
author | Govender, Kamini Chuturgoon, Anil |
author_facet | Govender, Kamini Chuturgoon, Anil |
author_sort | Govender, Kamini |
collection | PubMed |
description | The COVID-19 pandemic caused by SARS-CoV-2 has placed severe constraints on healthcare systems around the globe. The SARS-CoV-2 virus has caused upheaval in the healthcare and economic sectors worldwide. On the 20th of May 2020, the World Health Organisation declared COVID-19 a global pandemic due to the unprecedented number of cases reported around the globe. As of the 4th of November 2022, there were 637,117,429 coronavirus cases reported globally by Worldometer stats, with 6,602,572 related deaths. In South Africa, there were approximately 4,029,496 coronavirus cases and 102,311 associated deaths. As such, there is a need for efficacious therapeutic regimes. There has been a paucity of knowledge encompassing the use of effective and specific antiviral drug therapies for treating COVID-19 since the outbreak. In this review, we provide valuable insights into the repurposing of current drugs for COVID-19. Drug repurposing provides a suitable option for the discovery of efficacious drugs for COVID-19, thereby decreasing the costs and turnaround times of drug development strategies. This review provides an overview of ten drugs, including antimalarial, antiparasitic, anti-inflammatory, nucleoside analogue, monoclonal-antibody drugs, that were repurposed for the potential treatment of COVID-19. |
format | Online Article Text |
id | pubmed-9774286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97742862022-12-23 An Overview of Repurposed Drugs for Potential COVID-19 Treatment Govender, Kamini Chuturgoon, Anil Antibiotics (Basel) Review The COVID-19 pandemic caused by SARS-CoV-2 has placed severe constraints on healthcare systems around the globe. The SARS-CoV-2 virus has caused upheaval in the healthcare and economic sectors worldwide. On the 20th of May 2020, the World Health Organisation declared COVID-19 a global pandemic due to the unprecedented number of cases reported around the globe. As of the 4th of November 2022, there were 637,117,429 coronavirus cases reported globally by Worldometer stats, with 6,602,572 related deaths. In South Africa, there were approximately 4,029,496 coronavirus cases and 102,311 associated deaths. As such, there is a need for efficacious therapeutic regimes. There has been a paucity of knowledge encompassing the use of effective and specific antiviral drug therapies for treating COVID-19 since the outbreak. In this review, we provide valuable insights into the repurposing of current drugs for COVID-19. Drug repurposing provides a suitable option for the discovery of efficacious drugs for COVID-19, thereby decreasing the costs and turnaround times of drug development strategies. This review provides an overview of ten drugs, including antimalarial, antiparasitic, anti-inflammatory, nucleoside analogue, monoclonal-antibody drugs, that were repurposed for the potential treatment of COVID-19. MDPI 2022-11-22 /pmc/articles/PMC9774286/ /pubmed/36551336 http://dx.doi.org/10.3390/antibiotics11121678 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Govender, Kamini Chuturgoon, Anil An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title | An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title_full | An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title_fullStr | An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title_full_unstemmed | An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title_short | An Overview of Repurposed Drugs for Potential COVID-19 Treatment |
title_sort | overview of repurposed drugs for potential covid-19 treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774286/ https://www.ncbi.nlm.nih.gov/pubmed/36551336 http://dx.doi.org/10.3390/antibiotics11121678 |
work_keys_str_mv | AT govenderkamini anoverviewofrepurposeddrugsforpotentialcovid19treatment AT chuturgoonanil anoverviewofrepurposeddrugsforpotentialcovid19treatment AT govenderkamini overviewofrepurposeddrugsforpotentialcovid19treatment AT chuturgoonanil overviewofrepurposeddrugsforpotentialcovid19treatment |